Wave Life Sci Ord Sh (WVE)

Mar 27, 2025, 3:54 PM EDT - 27 days ago

Wave Life Sciences: Potential For Accelerated Approval Pathway With WVE-N531

Mar 26, 2025, 10:21 AM EDT - 4 weeks ago

Wave Life Sciences Stock Jumps On Positive Data From Muscle Disorder Drug, Plans FDA Submission Next Year

Mar 26, 2025, 7:30 AM EDT - 4 weeks ago

Wave Life Sciences Announces Positive Data from FORWARD-53 Clinical Trial in DMD Including Significant Functional Benefit and Reversal of Muscle Damage after 48 Weeks of Dosing with WVE-N531

Mar 4, 2025, 3:16 PM EST - 7 weeks ago

Wave Life Sciences Ltd. (WVE) Q4 2024 Earnings Call Transcript

Mar 4, 2025, 7:30 AM EST - 7 weeks ago

Wave Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 25, 2025, 8:30 AM EST - 2 months ago

Wave Life Sciences Fourth Quarter and Full Year 2024 Financial Results Scheduled for March 4, 2025

Feb 6, 2025, 8:30 AM EST - 2 months ago

Wave Life Sciences Announces Initiation of Phase 1 INLIGHT Clinical Trial of WVE-007 in Obesity

Jan 8, 2025, 1:35 AM EST - 3 months ago

Wave Life Sciences Is A Buy On Pipeline Prospects

Dec 23, 2024, 8:30 AM EST - 4 months ago

Wave Life Sciences Announces Submission of First Clinical Trial Application for WVE-007 (siRNA Targeting INHBE) in Obesity

Dec 16, 2024, 8:30 AM EST - 4 months ago

Wave Life Sciences to Present at 43rd Annual J.P. Morgan Healthcare Conference

Nov 15, 2024, 8:30 AM EST - 5 months ago

Wave Life Sciences to Present at Jefferies London Healthcare Conference

Nov 12, 2024, 12:20 PM EST - 5 months ago

Wave Life Sciences Ltd. (WVE) Q3 2024 Earnings Call Transcript

Oct 30, 2024, 4:45 PM EDT - 6 months ago

Wave Life Sciences Highlights Growing Pipeline at Research Day, including INHBE siRNA Program for Obesity and New RNA Editing Programs

Oct 16, 2024, 4:43 PM EDT - 6 months ago

Wave Life Sciences: Positive WVE-006 Data For AATD Leads To 2025 Catalyst

Oct 16, 2024, 2:43 PM EDT - 6 months ago

This Cisco Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday

CSCO GWW SAP WLK

Oct 16, 2024, 11:19 AM EDT - 6 months ago

Wave Life Sciences Reveals RNA Editing Breakthrough, Reports First-Ever Clinical Proof-Of-Mechanism In Humans

Oct 16, 2024, 8:25 AM EDT - 6 months ago

Wave Life Sciences Announces Upcoming Virtual Research Day on Wednesday, October 30, 2024

Oct 1, 2024, 9:20 AM EDT - 7 months ago

Wave Life Sciences Announces Closing of Upsized Public Offering of Ordinary Shares and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares

Sep 30, 2024, 8:30 AM EDT - 7 months ago

Wave Life Sciences to Present at Chardan 8th Annual Genetic Medicines Conference

Sep 26, 2024, 12:05 PM EDT - 7 months ago

Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut

Sep 25, 2024, 9:14 PM EDT - 7 months ago

Wave Life Sciences Prices Upsized $200 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Sep 24, 2024, 4:01 PM EDT - 7 months ago

Wave Life Sciences Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants

Sep 24, 2024, 1:41 PM EDT - 7 months ago

Wave Life Sciences' stock soars 51% after biotech posts positive data from Duchenne muscular-dystrophy trial

Sep 24, 2024, 7:30 AM EDT - 7 months ago

Wave Life Sciences Announces Positive Interim Data from FORWARD-53 Clinical Trial Evaluating WVE-N531 in Boys with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping

Aug 10, 2024, 10:27 AM EDT - 9 months ago

Wave Life Sciences Ltd. (WVE) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 7:30 AM EDT - 9 months ago

Wave Life Sciences Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 1, 2024, 8:30 AM EDT - 9 months ago

Wave Life Sciences Second Quarter 2024 Financial Results Scheduled for August 8, 2024

Jun 25, 2024, 9:37 AM EDT - 10 months ago

What's Going On With Wave Life Sciences Stock On Tuesday?

Jun 25, 2024, 7:30 AM EDT - 10 months ago

Wave Life Sciences Announces Positive Results from Phase 1b/2a SELECT-HD Trial with First Clinical Demonstration of Allele-Selective Mutant Huntingtin Lowering in Huntington's Disease

Jun 12, 2024, 8:30 AM EDT - 11 months ago

Wave Life Sciences Announces Upcoming Presentations Highlighting Novel siRNA Program in Obesity and Leadership in RNA Editing

May 30, 2024, 8:30 AM EDT - 11 months ago

Wave Life Sciences to Present at 2024 Jefferies Global Healthcare Conference

May 9, 2024, 7:30 AM EDT - 1 year ago

Wave Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update

May 9, 2024, 7:00 AM EDT - 1 year ago

Wave Life Sciences Announces Appointment of Dr. Erik Ingelsson as Chief Scientific Officer

May 7, 2024, 8:30 AM EDT - 1 year ago

Wave Life Sciences to Present at 2024 RBC Capital Markets Global Healthcare Conference

May 2, 2024, 8:30 AM EDT - 1 year ago

Wave Life Sciences First Quarter 2024 Financial Results Scheduled for May 9, 2024

Apr 30, 2024, 8:30 AM EDT - 1 year ago

Wave Life Sciences Announces Approval of First Clinical Trial Application for RestorAATion-2 Trial of WVE-006 in Individuals with Alpha-1 Antitrypsin Deficiency (AATD)

Apr 23, 2024, 8:30 AM EDT - 1 year ago

Wave Life Sciences Announces Continued Momentum in GSK Collaboration and Advancements in siRNA and RNA Editing

Mar 27, 2024, 8:30 AM EDT - 1 year ago

Wave Life Sciences to Present at Upcoming Investor Conferences

Mar 14, 2024, 5:34 PM EDT - 1 year ago

Newer Treatments In Alpha-1 Antitrypsin Deficiency: $2.5 Billion/Year Market Size By 2032

KRRO KRYS MREO TAK

Mar 6, 2024, 12:03 PM EST - 1 year ago

Wave Life Sciences Ltd. (WVE) Q4 2023 Earnings Call Transcript

Mar 6, 2024, 7:30 AM EST - 1 year ago

Wave Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Feb 28, 2024, 8:30 AM EST - 1 year ago

Wave Life Sciences Fourth Quarter and Full Year 2023 Financial Results Scheduled for March 6, 2024

Feb 27, 2024, 8:30 AM EST - 1 year ago

Wave Life Sciences Announces Upcoming Presentations at MDA Conference that Highlight Best-in-Class Potential for WVE-N531 in Duchenne Muscular Dystrophy

Jan 8, 2024, 8:00 AM EST - 1 year ago

Wave Life Sciences Highlights Recent Achievements and Upcoming 2024 Milestones

Jan 3, 2024, 8:30 AM EST - 1 year ago

Wave Life Sciences to Present at 42nd Annual J.P. Morgan Healthcare Conference

Dec 15, 2023, 8:30 AM EST - 1 year ago

Wave Life Sciences Announces Initiation of Dosing in Phase 2 FORWARD-53 Trial of WVE-N531 in Duchenne Muscular Dystrophy

Dec 7, 2023, 11:56 AM EST - 1 year ago

Wave Life Sciences stock slides 31% after company prices $100 million secondary share offering

Dec 7, 2023, 7:00 AM EST - 1 year ago

Wave Life Sciences Prices $100 Million Public Offering of Ordinary Shares

Dec 6, 2023, 4:08 PM EST - 1 year ago

Wave Life Sciences Announces Initiation of Dosing in RestorAATion Clinical Program Evaluating First-Ever RNA Editing Candidate, WVE-006, for Alpha-1 Antitrypsin Deficiency

Nov 22, 2023, 8:30 AM EST - 1 year ago

Wave Life Sciences to Present at 6ᵗʰ Annual Evercore ISI HealthCONx Conference